Research Topic: mucormycosis

Monoclonal Antibodies Can Aid in the Culture-Based Detection and Differentiation of Mucorales Fungi—The Flesh-Eating Pathogens Apophysomyces and Saksenaea as an Exemplar

Researchers developed a new diagnostic tool using specially designed antibodies to quickly identify dangerous flesh-eating fungi (Apophysomyces and Saksenaea) that cause severe infections. These fungi are particularly difficult to diagnose because they don’t produce spores on standard laboratory cultures. The new test can identify these pathogens in just 24-48 hours, much faster than traditional methods, which is critical since these infections progress rapidly and require immediate treatment. This advancement is especially important for hospitals in developing countries where expensive diagnostic equipment is unavailable.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

Isavuconazole is an antifungal medication used to treat serious fungal infections in people with weakened immune systems. This study reviewed and analyzed three clinical trials to compare how well isavuconazole works compared to other antifungal drugs. The results showed that isavuconazole is just as effective as other antifungals but has fewer side effects, particularly fewer problems with liver health and drug-related adverse events. This makes isavuconazole a good alternative choice for patients who cannot use other antifungal medications or who are at risk of liver damage.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Read More »

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report

A 74-year-old man with leukemia developed a serious fungal infection (mucormycosis) on his ankle while taking cancer-fighting drugs. The infection was diagnosed through tissue biopsy examination rather than standard culture tests. Treatment required both powerful antifungal medications and surgical removal of the infected leg below the knee. The patient recovered successfully after this aggressive treatment approach.

Read More »
Scroll to Top